Functional amino acids (FAAs) and α-aminoamides (AAAs) are two classes of antiepileptic drugs (AEDs) that exhibit pronounced anticonvulsant activities. We combined key structural pharmacophores present in FAAs and AAAs to generate a new series of compounds and document that select compounds exhibit activity superior to either the prototypical FAA (lacosamide) or the prototypical AAA (safinamide) in the maximal electroshock (MES) seizure model in rats. A representative compound, (R)-N-4′-((3″-fluoro)benzyloxy)benzyl 2-acetamido-3-methoxypropionamide ((R)-10), was tested in the MES (mice, ip), MES (rat, po), psychomotor 6 Hz (32 mA) (mice, ip), and hippocampal kindled (rat, ip) seizure tests providing excellent protection with ED50 values of ...
We report herein the design and optimization of a novel series of sulfamides and sulfamates derived ...
(R)-Lacosamide ((R)-2, (R)-N-benzyl 2-acetamido-3-methoxypropionamide), has recently gained regulato...
Pharmaceutical compositions comprise as the active ingredient potent orally active, nonneurotoxic an...
Functional amino acids (FAAs) and α-aminoamides (AAAs) are two classes of antiepileptic drugs (AEDs)...
Primary Amino Acid Derivatives (PAADs) (N′-benzyl 2-substituted 2-amino acetamides) are structurally...
The functionalized amino acid, lacosamide ((R)-2), and the α-aminoamide, safinamide ((S)-3), are neu...
Six novel 3″-substituted (R)-N-(phenoxybenzyl) 2-N-acetamido-3-methoxypropionamides were prepared an...
Six novel 3″-substituted (R)-N-(phenoxybenzyl) 2-N-acetamido-3-methoxypropionamides were prepared an...
The functionalized amino acid, lacosamide ((R)-2), and the α-aminoamide, safinamide ((S)-3), are neu...
We recently reported that merging key structural pharmacophores of the anticonvulsant drugs lacosami...
The structure-activity relationship (SAR) for the N-benzyl group in the clinical antiepileptic agent...
Sulfamides are promising functions for the design of new antiepileptic drugs (Bioorg. Med. Chem. 200...
Abstract Quantitative structure-activity relationship study was done on 62 compounds with anticonvul...
Lacosamide ((R)-N-benzyl 2-acetamido-3-methoxypropionamide, (R)-1) is a low molecular weight anticon...
The hypothesis that certain amino acid analogues possessing a five-membered ring structure or amino ...
We report herein the design and optimization of a novel series of sulfamides and sulfamates derived ...
(R)-Lacosamide ((R)-2, (R)-N-benzyl 2-acetamido-3-methoxypropionamide), has recently gained regulato...
Pharmaceutical compositions comprise as the active ingredient potent orally active, nonneurotoxic an...
Functional amino acids (FAAs) and α-aminoamides (AAAs) are two classes of antiepileptic drugs (AEDs)...
Primary Amino Acid Derivatives (PAADs) (N′-benzyl 2-substituted 2-amino acetamides) are structurally...
The functionalized amino acid, lacosamide ((R)-2), and the α-aminoamide, safinamide ((S)-3), are neu...
Six novel 3″-substituted (R)-N-(phenoxybenzyl) 2-N-acetamido-3-methoxypropionamides were prepared an...
Six novel 3″-substituted (R)-N-(phenoxybenzyl) 2-N-acetamido-3-methoxypropionamides were prepared an...
The functionalized amino acid, lacosamide ((R)-2), and the α-aminoamide, safinamide ((S)-3), are neu...
We recently reported that merging key structural pharmacophores of the anticonvulsant drugs lacosami...
The structure-activity relationship (SAR) for the N-benzyl group in the clinical antiepileptic agent...
Sulfamides are promising functions for the design of new antiepileptic drugs (Bioorg. Med. Chem. 200...
Abstract Quantitative structure-activity relationship study was done on 62 compounds with anticonvul...
Lacosamide ((R)-N-benzyl 2-acetamido-3-methoxypropionamide, (R)-1) is a low molecular weight anticon...
The hypothesis that certain amino acid analogues possessing a five-membered ring structure or amino ...
We report herein the design and optimization of a novel series of sulfamides and sulfamates derived ...
(R)-Lacosamide ((R)-2, (R)-N-benzyl 2-acetamido-3-methoxypropionamide), has recently gained regulato...
Pharmaceutical compositions comprise as the active ingredient potent orally active, nonneurotoxic an...